Mostrar el registro sencillo del ítem

dc.contributor.authorLópez-Gómez, Carlos
dc.contributor.authorOliver-Martos, Begoña 
dc.contributor.authorPinto-Medel, María Jesús
dc.contributor.authorSuardíaz García, Margarita
dc.contributor.authorReyes-Garrido, Virginia
dc.contributor.authorUrbaneja, Patricia
dc.contributor.authorFernández-Fernández, Óscar
dc.contributor.authorLeyva-Fernández, Laura 
dc.date.accessioned2024-09-30T13:41:55Z
dc.date.available2024-09-30T13:41:55Z
dc.date.issued2016
dc.identifier.citationLópez-Gómez C, Oliver-Martos B, Pinto-Medel MJ, Suardiaz M, Reyes-Garrido V, Urbaneja P, Fernández Ó, Leyva L. TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic response. J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):130-7. doi: 10.1136/jnnp-2014-309932. Epub 2015 Mar 3. PMID: 25736057; PMCID: PMC4752633.es_ES
dc.identifier.urihttps://hdl.handle.net/10630/34074
dc.description.abstractObjective We aimed to assess the effects of interferon β (IFNβ) treatment on the expression of the splice variants of the Tumour necrosis factor-Related Apoptosis Inducing Ligand (TRAIL) and its receptors in different cell subpopulations (CD14+, CD4+ and CD8+) from patients with multiple sclerosis (MS), and to determine whether this expression discriminated responders from non-responders to IFNβ therapy. Methods We examined mRNA expression of the TRAIL and TRAIL receptors variants in patients with MS, at baseline and after one year of IFNβ therapy, according to responsiveness to this drug. Results Long-term therapy with IFNβ increased the expression of TRAIL-α in T cell subsets exclusively from responders and decreased the expression of the isoform 2 of TRAILR-2 in monocytes from responders as well as non-responders. Lower expression of TRAIL-α, and higher expression of TRAIL-β in monocytes and T cells, was found before the onset of IFNβ therapy in patients who will subsequently become responders. Baseline expression of TRAILR-1 was also significantly higher in monocytes and CD4+ T cells from responders. Conclusions The present study shows that long-term IFNβ treatment has a direct influence on TRAIL-α and TRAILR-2 isoform 2 expression. Besides, receiver operating characteristic analysis revealed that the baseline expression of TRAIL-α in monocytes and T cells, and that of TRAILR-1 in monocytes and CD4+ T cells, showed a predictive value of the clinical response to IFNβ therapy, pointing to a role of TRAIL system in the mechanism of action of IFNβ in MS that will need further investigation.es_ES
dc.language.isoenges_ES
dc.publisherBMJ Journalses_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectEsclerosis múltiplees_ES
dc.subject.otherTRAILes_ES
dc.subject.otherIFN betaes_ES
dc.subject.otherMultiple sclerosises_ES
dc.titleTRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic responsees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.identifier.doi10.1136/jnnp-2014-309932
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersiones_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem